Apogee Therapeutics Aktie News

Apogee Therapeutics, Inc.'s APG777 shows best-in-class week-16 efficacy and quarterly/semi-annual dosing potential. In my view, this could give this drug candidate a great competitive profile. In fact, APG777 could potentially disrupt the massive AT market, which is currently dominated by Dupixent. APGE's Phase 2 trial, called APEX Part A, exceeded its targets. We also have to wait until 1H2026...

Apogee Therapeutics (NASDAQ:APGE) shares fell almost 15% despite the release of positive Phase 2 APEX trial results for APG777, its anti-IL-13 antibody for moderate-to-severe atopic dermatitis. The trial met its primary endpoint with a 71% reduction in Eczema Area Severity Index (EASI) score at Week 16, versus 33.8% for placebo.

Apogee Therapeutics shares crumbled Monday despite promising results for what could become a quarterly or twice-yearly shot to control eczema.

APEX Part A met all primary and key secondary endpoints and exceeded trial objectives, including 7 1.0% decrease  from baseline in EASI at Week 16

SAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with the potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructiv...

SAN FRANCISCO and BOSTON, May 29, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 10:30 a.m. E.T.

Apogee Therapeutics, Inc. achieved positive interim results from phase 1b study using APG808 for the treatment of patients with Asthma. Interim 16-week data from the phase 2 APEX study using APG777 for the treatment of patients with AD expected mid-2025. The global asthma treatment market size is projected to reach $35.93 billion by 2034.

Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling